ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "infliximab"

  • Abstract Number: 2411 • 2014 ACR/ARHP Annual Meeting

    Assessing Treatment Durability of Infliximab in the Management of Psoriatic Arthritis and Rheumatoid Arthritis Patients in a Canadian Setting

    John Kelsall1, Algis Jovaisas2, Proton Rahman3, Dalton Sholter4, Michael Starr5, William Bensen6, Maqbool Sheriff7, Wojciech Olszynski8, Michel Zummer9, Rafat Faraawi10, Andrew Chow11, Suneil Kapur12, Emmanouil Rampakakis13, John S. Sampalis13, Francois Nantel14, Susan Otawa15, May Shawi14 and Allen J Lehman15, 1The Mary Pack Arthritis Centre, Vancouver, BC, Canada, 2194 Main Street, University of Ottawa, Ottawa, ON, Canada, 3Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, 4University of Alberta, Edmonton, AB, Canada, 5Rheumatology, McGill University Health Centre, Montreal, QC, Canada, 6St Josephs Hospital and McMaster University, Hamilton, ON, Canada, 7Nanaimo Regional General Hospital, Nanaimo, BC, Canada, 8University of Saskatchewan, Saskatoon, SK, Canada, 9Université de Montréal, Montreal, QC, Canada, 10Medicine, McMaster University, Hamilton, ON, Canada, 11McMaster University, Hamilton and Credit Valley Hospital, Mississauga, ON, Canada, 12Rheumatology, University of Ottawa, Ottawa, ON, Canada, 13JSS Medical Research, Montreal, QC, Canada, 14Janssen Inc., Toronto, ON, Canada, 15Medical Affairs, Janssen Inc., Toronto, ON, Canada

    Background/Purpose: The efficacy of anti-TNF in the management of psoriatic arthritis (PsA) and rheumatoid arthritis (RA) has been demonstrated in numerous controlled clinical trials. The…
  • Abstract Number: 2269 • 2014 ACR/ARHP Annual Meeting

    Efficacy and Safety of High Dose Infliximab in the Treatment of Uveitis in Pediatric Patients

    Liza Mariel Bermudez1, Patricia Irigoyen1, Anca Askanase2, Michael Weiss3, Joyce Hui-Yuen1, Amy J. Starr2, Lisa F. Imundo4, Andrew H. Eichenfield2 and Josephine Isgro1, 1Pediatric Rheumatology, Columbia University Medical Center, New York, NY, 2Columbia University Medical Center, New York, NY, 3Division of Ophthalmology Uveitis Service College of Physician And Surgeons of Columbia University, New York, NY, 4Assoociate Professor of Pediatrics in Medicine - Rheumatoology, Columbia University Medical Center, New York, NY

    Background/Purpose Chronic uveitis, an inflammatory eye disease, is a leading causes of childhood blindness and often has a chronic recurrent course. This study reviews the efficacy and safety of high…
  • Abstract Number: 1839 • 2014 ACR/ARHP Annual Meeting

    Risk of Recurrent Non-Melanoma Skin Cancer with Methotrexate and Anti-TNF Use in Rheumatoid Arthritis

    Frank I Scott1, Ronac Mamtani1, Colleen Brensinger1, Kevin Haynes2, Zelma ChiesaFuxench1, Huifeng Yun3, Jie Zhang4, Lang Chen5, Fenglong Xie6, David Margolis7, James D. Lewis2 and Jeffrey R. Curtis8, 1University of Pennsylvania, Philadelphia, PA, 2Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 3Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, 4Ryals Soph Bldg., Rm. 517b, Univ. of Alabama at Birmingham, Birmingham, AL, 5Medicine, University of Alabama at Birmingham, Birmingham, AL, 6Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, 7Dermatology and Epidemiology, University of Pennsylvania, Philadelphia, PA, 8The University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose:  Methotrexate (MTX) and anti-TNF drugs have been hypothesized to increase the risk of a first non-melanoma skin cancer (NMSC). Among patients with prior NMSC,…
  • Abstract Number: 1551 • 2014 ACR/ARHP Annual Meeting

    Correlation of Individual HAQ Questions with Disease Activity Measures in Psoriatic Arthritis: Implications for Instrument Reduction

    Denis Choquette1, Carter Thorne2, Majed Khraishi3, Isabelle Fortin4, Regan Arendse5, Andrew Chow6, John Kelsall7, Milton Baker8, Julie Vaillancourt9, John S. Sampalis9, Francois Nantel10, Allen J Lehman11, Susan Otawa11 and May Shawi10, 1Rheumatology, Notre Dame Hospital, Montreal, QC, Canada, 2Southlake Regional Health Centre, Newmarket, ON, Canada, 3Nexus Clinical Research, St John's, NF, Canada, 4Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, 5University of Saskatchewan, Saskatoon, SK, Canada, 6University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, 7The Mary Pack Arthritis Centre, Vancouver, BC, Canada, 8University of Victoria, Victoria, BC, Canada, 9JSS Medical Research, Montreal, QC, Canada, 10Janssen Inc., Toronto, ON, Canada, 11Medical Affairs, Janssen Inc., Toronto, ON, Canada

    Background/Purpose The Health Assessment Questionnaire (HAQ) is commonly used for assessing patient-reported functional status and disease activity in psoriatic arthritis (PsA). However, it has been…
  • Abstract Number: 1397 • 2014 ACR/ARHP Annual Meeting

    Impact of Corticosteroid Use on Remission Sustainability and Infection Rates Among Rheumatoid Arthritis Patients in Remission While on Infliximab: Treatment Implications Based on a Real-World Canadian Population

    Boulos Haraoui1, Algis Jovaisas2, William G. Bensen3, Rafat Faraawi4, John Kelsall5, Sanjay Dixit4, Jude Rodrigues6, Maqbool Sheriff7, Emmanouil Rampakakis8, John S. Sampalis8, Allen J Lehman9, Susan Otawa9, Francois Nantel10 and May Shawi10, 1Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, 2Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, 3Department of Medicine, Division of Rheumatology, St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, 4McMaster University, Hamilton, ON, Canada, 5The Mary Pack Arthritis Centre, Vancouver, BC, Canada, 6Clinical Research and Arthritis Centre, Windsor, ON, Canada, 7Nanaimo Regional General Hospital, Nanaimo, BC, Canada, 8JSS Medical Research, Montreal, QC, Canada, 9Medical Affairs, Janssen Inc., Toronto, ON, Canada, 10Janssen Inc., Toronto, ON, Canada

    Background/Purpose The Canadian Rheumatology Association1 recommends that addition of corticosteroids (CS) should be considered only for the shortest period possible in rheumatoid arthritis (RA) patients…
  • Abstract Number: 402 • 2014 ACR/ARHP Annual Meeting

    Can GP88 (Progranulin) be Used As a Biomarker for the Diagnosis and Therapy Evaluation of Rheumatoid Arthritis?

    Masao Sato1,2, Masao Takemura2,3, Kuniaki Saito4 and Yasuko Yamamoto4, 1Rheumatology, Matsunami General Hospital, Gifu, Japan, 2Matsunami Reserch Park, Gifu, Japan, 3Informative Laboratory Merdicine, Gifu University, Gifu, Japan, 4Human Health Science, Kyoto University, Kyoto, Japan

    Background/Purpose GP88 (progranulin; PGRN), a glycoprotein with a molecular weight of approximately 88000, is suggested to play an important role in the immune response and…
  • Abstract Number: 365 • 2014 ACR/ARHP Annual Meeting

    Differential Relative Contribution of Individual Components on DAS28 over Time: An Analysis from the Prospective, Observational, Biological Treatment Registry Across Canada

    Denis Choquette1, Dalton Sholter2, Isabelle Fortin3, Michael Starr4, Carter Thorne5, Milton Baker6, Regan Arendse7, Philip Baer8, Michel Zummer9, Jude Rodrigues10, Maqbool Sheriff11, Emmanouil Rampakakis12, John S. Sampalis12, Francois Nantel13, Allen J Lehman14, Susan Otawa14 and May Shawi13, 1Rheumatology, Notre Dame Hospital, Montreal, QC, Canada, 2University of Alberta, Edmonton, AB, Canada, 3Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, 4Montreal General Hospital, Montreal, QC, Canada, 5Southlake Regional Health Centre, Newmarket, ON, Canada, 6University of Victoria, Victoria, BC, Canada, 7University of Saskatchewan, Saskatoon, SK, Canada, 8Private Practice, Scarborough, ON, Canada, 9Université de Montréal, Montreal, QC, Canada, 10Clinical Research and Arthritis Centre, Windsor, ON, Canada, 11Nanaimo Regional General Hospital, Nanaimo, BC, Canada, 12JSS Medical Research, Montreal, QC, Canada, 13Janssen Inc., Toronto, ON, Canada, 14Medical Affairs, Janssen Inc., Toronto, ON, Canada

    Background/Purpose DAS28 is an important outcome for clinical research and practice assisting with therapeutic decisions. The main contributors to DAS28 are joint tenderness and acute-phase…
  • Abstract Number: 248 • 2014 ACR/ARHP Annual Meeting

    Is the Basdai Score Driven By Pain in Ankylosing Spondylitis Patients Treated with Anti-TNF?

    Proton Rahman1, Algis Jovaisas2, William Bensen3, Wojciech Olszynski4, Anna Jaroszynska5, Philip Baer6, Maqbool Sheriff7, Dalton Sholter8, Eliofotisti Psaradellis9, John S. Sampalis9, Francois Nantel10, Allen J Lehman11, Susan Otawa11 and May Shawi10, 1Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, 2194 Main Street, University of Ottawa, Ottawa, ON, Canada, 3Division of Rheumatology, McMaster University, Hamilton, ON, Canada, 4University of Saskatchewan, Saskatoon, SK, Canada, 5Private Practice, Burlington, ON, Canada, 6Private Practice, Scarborough, ON, Canada, 7Nanaimo Regional General Hospital, Nanaimo, BC, Canada, 8University of Alberta, Edmonton, AB, Canada, 9JSS Medical Research, Montreal, QC, Canada, 10Janssen Inc., Toronto, ON, Canada, 11Medical Affairs, Janssen Inc., Toronto, ON, Canada

    Background/Purpose The present standard for measuring disease activity in AS is the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) which focuses on five major symptoms…
  • Abstract Number: L14 • 2014 ACR/ARHP Annual Meeting

    Determination of Efficacy of Intra-Articular Infliximab Therapy in JIA Patients By 3D/4D Musculo-Skeletal Ultrasound

    Miroslav Harjacek1, Mandica Vidovic2, Lovro Lamot2,3, Marija Perica2 and Lana Tambic Bukovac2, 1Rheumatology, Children's Hospital Srebrnjak, Zagreb, Croatia, 2Children's Hospital Srebrnjak, Zagreb, Croatia, 3University of Zagreb School of Medicine, Zagreb, Croatia

    Background/Purpose: Intra-articular (IA) infliximab (IFX) is an attractive treatment option of chronic arthritis, but based on few heterogenic studies, outcome is still controversial. To investigate…
  • Abstract Number: 499 • 2013 ACR/ARHP Annual Meeting

    Efficacy and Safety Of Infliximab Or Adalimumab Vs Abatacept In Patients With Rheumatoid Arthritis and An Inadequate Response To Methotrexate: Attest-Ample Network Randomized Trial

    Robin Christensen1, Simon Tarp1, Daniel Furst2, Lars E. Kristensen3 and Henning Bliddal4, 1Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, 2David Geffen School of Medicine, University of California, Los Angeles, CA, 3Rheumatology, Department of Clinical Sciences, Lund, Section of Rheumatology, Lund University, Lund, Sweden, 4Department of Rheumatology, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark

    Background/Purpose: Using combined data from the ATTEST [1] and AMPLE [2] study comparing infliximab and adalimumab with abatacept in patients with rheumatoid arthritis (RA), we…
  • Abstract Number: 473 • 2013 ACR/ARHP Annual Meeting

    Real-World Effectiveness and Safety Of Infliximab In The Treatment Of Rheumatoid Arthritis Over 5 Years: The Canadian Experience

    Denis Choquette1, William Bensen2, Andrew Chow3, John T. Kelsall4, Maqbool K. Sheriff5, Jude F. Rodrigues6, Emmanouil Rampakakis7, John S. Sampalis7, May Shawi8, Francois Nantel9, Susan M. Otawa10 and Allen J. Lehman10, 1Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, 2St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, 3University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, 4Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, 5Nanaimo Regional General Hospital, Nanaimo, BC, Canada, 6Rheumatology, Windsor, ON, Canada, 7JSS Medical Research, Montreal, QC, Canada, 8Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada, 9Janssen Inc., Toronto, ON, Canada, 10Medical Affairs, Janssen Inc., Toronto, ON, Canada

    Background/Purpose:   Efficacy and safety of anti-TNF in rheumatoid arthritis (RA) management has been demonstrated in numerous controlled clinical trials. Longitudinal observational studies assessing the…
  • Abstract Number: 452 • 2013 ACR/ARHP Annual Meeting

    What Are The Implications Of Concomitant and Pre-Medication On Infusion Reactions To Infliximab: Results From “RemiTRAC Infusion”, a Prospective Real-World Community Registry

    Denis Choquette1, Rafat Y. Faraawi2,3, Merlin Njoya4, Andrew Chow5, William G. Bensen6 and Francois Nantel7, 1Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, 2Rheumatologist, KW Musculoskeletal Research Inc., Kitchener, ON, Canada, 3McMaster University, Hamilton, ON, Canada, 4McKesson Canada, Toronto, ON, Canada, 5University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, 6Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, 7Janssen Inc., Toronto, ON, Canada

    Background/Purpose: Infliximab (IFX) is a therapeutic monoclonal antibody targeting TNFa indicated in the treatment of a number of chronic inflammatory diseases. IFX is administered by…
  • Abstract Number: 427 • 2013 ACR/ARHP Annual Meeting

    US Veterans With Rheumatoid Arthritis Who Switch Among Tumor Necrosis Factor Blocking Agents Have No Additional Clinical Benefit With The Change In Therapy and Incur Higher Costs

    Grant W. Cannon1, Scott L. DuVall2, Candace L. Hayden3, Liron Caplan4, Jeffrey R. Curtis5, Kaleb Michaud6, Ted R. Mikuls7, Andreas M. Reimold8, David H. Collier9, George Joseph9, David J. Harrison9 and Brian C. Sauer10, 1Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT, 2VA Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, 3Epidemiology, VA Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, 4Department of Medicine, Denver Veterans Affairs Medical Center, Denver, CO, 5Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 6Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE, 7Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 8Rheumatology, Dallas VA and University of Texas Southwestern, Dallas, TX, 9Amgen Inc., Thousand Oaks, CA, 10Epdemiology, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT

    Background/Purpose:  While tumor necrosis factor (TNF) blockers can be effective in treating rheumatoid arthritis (RA), the benefit of switching among TNF blockers is not clear.…
  • Abstract Number: 314 • 2013 ACR/ARHP Annual Meeting

    Impact Of Low Infliximab Dose Regimen On Treatment Response and Drug Survival In 462 Patients With Psoriatic Arthritis. Results From The Nationwide Registries Danbio and Icebio

    Bente Glintborg1,2, Bjorn Gudbjornsson3,4, Niels Steen Krogh5, Emina Omerovic2, Natalia Manilo6, Mette Holland-Fischer7, Hanne M. Lindegaard8, Anne Gitte Loft9, Henrik Nordin10, Laura Johnsen11, Sussi Flejsborg Oeftiger12, Annette Hansen13, Claus Rasmussen14, Gerdur Grondal15, Árni Jón Geirsson16 and Merete Lund Hetland1,2,17, 1The Danish Rheumatologic Database (DANBIO), Glostrup Hospital, Glostrup, Denmark, 2Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup, Denmark, 3Department of Rheumatology, Center for Rheumatology Research (ICEBIO), Landspitali – The National University Hospital of Iceland, Reykjavik, Iceland, 4Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 5ZiteLab ApS, Copenhagen, Denmark, 6Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Denmark, 7Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, 8Department of Rheumatology, Odense University Hospital, Odense, Denmark, 9Department of Rheumatology, Sygehus Lillebaelt, Vejle, Denmark, 10Department of Infectious Diseases and Rheumatology, Rigshospitalet, Copenhagen, Denmark, 11Department of Rheumatology, Helsingør and Hillerød Hospital, Hillerød, Denmark, 12Department of Rheumatology, Køge Hospital, Køge, East Timor, 13Department of Rheumatology, Gentofte University Hospital, Copenhagen, Denmark, 14Vendsyssel Teaching Hospital/Aalborg University, Hjoerring, Denmark, 15Department of Rheumatology, Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland, 16Rheumatology, Department of Rheumatology, Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland, 17Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark

    Background/Purpose: International guidelines recommend that in psoriatic arthritis infliximab should be dosed with 5 mg/kg bodyweight every 8th week. Data on the use of lower…
  • Abstract Number: 2458 • 2013 ACR/ARHP Annual Meeting

    Change Over Time In The Profile Of Ankylosing Spondylitis Patients Treated With Infliximab In Canadian Routine Care

    Denis Choquette1, Michael Starr2, Majed M. Khraishi3, William G. Bensen4, Saeed A. Shaikh5, Jude F. Rodrigues6, Dalton E. Sholter7, Maqbool K. Sheriff8, Julie Vaillancourt9, John S. Sampalis9, Allen J. Lehman10, Susan M. Otawa10, Francois Nantel11 and May Shawi12, 1Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, 2Montreal General Hospital, Montreal, QC, Canada, 3Nexus Clinical Research, St John's, NF, Canada, 4Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, 5Medicine, McMaster University, St Catharines, ON, Canada, 6Rheumatology, Windsor, ON, Canada, 7Rheumatology Associates, Edmonton, AB, Canada, 8Nanaimo Regional General Hospital, Nanaimo, BC, Canada, 9JSS Medical Research, Montreal, QC, Canada, 10Medical Affairs, Janssen Inc., Toronto, ON, Canada, 11Janssen Inc., Toronto, ON, Canada, 12Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada

    Background/Purpose: Canadian provincial reimbursement policies in regards with infliximab coverage status have evolved in the last decade. The objective of this study was to describe…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies